DT-Web

DB01295 - Bevantolol


Identification
Name Bevantolol
Accession Number DB01295
Type small molecule
Description Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 345.4327
Groups approved
Monoisotopic Weight 345.194008357
Pharmacology
Indication For the treatment of angina pectoris and hypertension.
Mechanism of action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.
Absorption Not Available
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Chlorpropamide The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
Clonidine Increased hypertension when clonidine stopped
Dihydroergotamine Ischemia with risk of gangrene
Disopyramide The beta-blocker, bevantolol, may increase the toxicity of disopyramide.
Epinephrine Hypertension, then bradycardia
Ergotamine Ischemia with risk of gangrene
Fenoterol Antagonism
Formoterol Antagonism
Gliclazide The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
Glyburide The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
Ibuprofen Risk of inhibition of renal prostaglandins
Indomethacin Risk of inhibition of renal prostaglandins
Insulin Glargine The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
Methysergide Ischemia with risk of gangrene
Orciprenaline Antagonism
Pipobroman Antagonism
Piroxicam Risk of inhibition of renal prostaglandins
Prazosin Risk of hypotension at the beginning of therapy
Repaglinide The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.
Terbutaline Antagonism
Food Interactions Not Available

Targets


Beta-1 adrenergic receptor
Name Beta-1 adrenergic receptor
Gene Name ADRB1
Pharmacological action yes
Actions antagonist
References
  • Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8. - Pubmed
  • Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. - Pubmed
  • Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. - Pubmed
  • Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. - Pubmed
  • Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. - Pubmed
DTHybrid score 0.7052
Beta-2 adrenergic receptor
Name Beta-2 adrenergic receptor
Gene Name ADRB2
Pharmacological action unknown
Actions antagonist
References
  • Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. - Pubmed
DTHybrid score 0.7133
Alpha-1A adrenergic receptor
Name Alpha-1A adrenergic receptor
Gene Name ADRA1A
Pharmacological action unknown
Actions antagonist
References
  • Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. - Pubmed
DTHybrid score 0.3204

Predictions


Id Partner name Gene Name Score
4119 Cytochrome P450 2D6 CYP2D6 0.1462
1517 Beta-3 adrenergic receptor ADRB3 0.138
318 Alpha-2A adrenergic receptor ADRA2A 0.1139
632 Alpha-1B adrenergic receptor ADRA1B 0.0992
1588 Multidrug resistance protein 1 ABCB1 0.0736
320 5-hydroxytryptamine 1A receptor HTR1A 0.0717
4512 Cytochrome P450 3A4 CYP3A4 0.0644
789 Alpha-1D adrenergic receptor ADRA1D 0.0594
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0539
4200 Cytochrome P450 1A2 CYP1A2 0.0482
629 Alpha-2B adrenergic receptor ADRA2B 0.0418
6144 Solute carrier family 22 member 2 SLC22A2 0.0381
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0373
831 D(2) dopamine receptor DRD2 0.0371
502 5-hydroxytryptamine 2A receptor HTR2A 0.0369
378 Alpha-2C adrenergic receptor ADRA2C 0.0358
3923 Cholinesterase BCHE 0.0355
23 D(1A) dopamine receptor DRD1 0.0355
885 5-hydroxytryptamine 1B receptor HTR1B 0.035
6016 Cytochrome P450 2C19 CYP2C19 0.0336
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0313
131 Synaptic vesicular amine transporter SLC18A2 0.0301
6145 Solute carrier family 22 member 1 SLC22A1 0.0284
492 Histamine H1 receptor HRH1 0.028
824 Sodium-dependent serotonin transporter SLC6A4 0.0267
3941 Amine oxidase [flavin-containing] A MAOA 0.0256
713 Sodium-dependent dopamine transporter SLC6A3 0.0252
2300 Lysozyme E 0.0243
3633 Lysozyme R 0.0243
5597 Lysozyme 17 0.0243
3810 Catechol O-methyltransferase COMT 0.0211
6024 Cytochrome P450 1A1 CYP1A1 0.0206
828 Phenylalanine-4-hydroxylase PAH 0.0195
3109 Phenylalanine-4-hydroxylase phhA 0.0195
4757 Cytochrome P450 2C9 CYP2C9 0.019
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0179
590 5-hydroxytryptamine 2C receptor HTR2C 0.0169
1820 Beta-nerve growth factor NGF 0.0166
6040 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.016
4146 Phosphatidylinositol 3-kinase regulatory subunit gamma PIK3R3 0.0151
4145 Phosphatidylinositol 3-kinase regulatory subunit beta PIK3R2 0.0151
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0143
432 D(4) dopamine receptor DRD4 0.0142
4118 Cytochrome P450 3A5 CYP3A5 0.014
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0139
6107 Cytochrome P450 3A7 CYP3A7 0.013
6147 Solute carrier family 22 member 3 SLC22A3 0.0128
1281 Phosphatidylinositol 3-kinase regulatory subunit alpha PIK3R1 0.0125
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0124
4292 Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase lpxA 0.0124
3076 Antigen 85-C fbpC 0.0122
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0121
638 D(3) dopamine receptor DRD3 0.0115
6013 Cytochrome P450 2E1 CYP2E1 0.0113
777 Tumor necrosis factor TNF 0.0112
5718 Cytochrome P450 2A6 CYP2A6 0.0111
1256 5-hydroxytryptamine 6 receptor HTR6 0.011
716 5-hydroxytryptamine 7 receptor HTR7 0.011
3876 Aromatic-L-amino-acid decarboxylase DDC 0.0104
118 Organic cation/carnitine transporter 2 SLC22A5 0.0103
6847 Lactase-phlorizin hydrolase LCT 0.0093
465 Calmodulin CALM1 0.0086
6030 Cytochrome P450 2B6 CYP2B6 0.0083
1176 Mitogen-activated protein kinase 1 MAPK1 0.0083
163 D(1B) dopamine receptor DRD5 0.0081
1374 Natriuretic peptides B NPPB 0.008
725 5-hydroxytryptamine 1D receptor HTR1D 0.008
1827 Gap junction alpha-1 protein GJA1 0.008
1908 Vascular cell adhesion protein 1 VCAM1 0.008
6164 POU domain, class 5, transcription factor 1 POU5F1 0.008
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0078
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0078
4924 Cytochrome P450 2C8 CYP2C8 0.0072
587 Serum albumin ALB 0.0069
3939 Amine oxidase [flavin-containing] B MAOB 0.0066
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0066
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0065
124 Histamine H2 receptor HRH2 0.0065
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0063
436 5-hydroxytryptamine 2B receptor HTR2B 0.006
3947 Xanthine dehydrogenase/oxidase XDH 0.006
183 Vascular endothelial growth factor A VEGFA 0.0059
6151 Monocarboxylate transporter 10 SLC16A10 0.0052
1360 Sphingomyelin phosphodiesterase SMPD1 0.0049
6432 Transporter snf 0.0045
6138 Multidrug resistance protein 3 ABCB4 0.0043
1636 Trace amine-associated receptor 1 TAAR1 0.0039
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.0038
20 Prostaglandin G/H synthase 1 PTGS1 0.0038
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0038
3426 Glutamine synthetase glnA 0.0037
3987 Glutamine synthetase GLUL 0.0037
233 Potassium channel subfamily K member 2 KCNK2 0.0037
528 5-hydroxytryptamine 1E receptor HTR1E 0.0037
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0035
6859 Protein S100-A4 S100A4 0.0035
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0034
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.0032
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.0032
474 Acetylcholinesterase ACHE 0.0032
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.0031
6106 Cytochrome P450 2C18 CYP2C18 0.0031
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0031
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0031
833 Organic cation/carnitine transporter 1 SLC22A4 0.0031
4120 NADPH--cytochrome P450 reductase POR 0.003
341 5-hydroxytryptamine 3 receptor HTR3A 0.0029
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0029
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.0028
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0027
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.0027
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0025
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0024
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0024
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.0024
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0017
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0017
1656 CYP2B protein CYP2B 0.0017
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0012
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0011
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0011
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0011
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.0011
776 Bile salt export pump ABCB11 0.001
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.0008
1618 High affinity nerve growth factor receptor NTRK1 0.0008
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0008
164 Histamine H4 receptor HRH4 0.0007
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0006
467 Delta-type opioid receptor OPRD1 0.0005
696 Kappa-type opioid receptor OPRK1 0.0005
1898 Cytochrome P450 1B1 CYP1B1 0.0004
↑